How to Find a Drug Rehab Facility: Vetting Criteria and Red Flags

Selecting a drug rehabilitation facility involves evaluating accreditation status, clinical staffing, treatment methodology, and regulatory compliance — factors that directly affect patient safety and treatment outcomes. This page covers the structural criteria used to assess rehab facilities, the red flags associated with substandard or predatory programs, and the decision boundaries that separate evidence-based care from unverified alternatives. The scope is national, drawing on standards established by federal agencies and recognized accreditation bodies.

Definition and Scope

A drug rehabilitation facility, in the context of US federal and state regulation, is any program providing organized services for individuals diagnosed with a substance use disorder (SUD) under the clinical criteria defined in the DSM-5. The Substance Abuse and Mental Health Services Administration (SAMHSA) maintains the National Survey of Substance Abuse Treatment Services (N-SSATS), which tracks more than 17,000 treatment facilities operating across the United States, offering services ranging from detox services through long-term residential treatment.

Facilities fall into two broad regulatory categories:

• Licensed programs: State-licensed under behavioral health or mental health authority, required to meet minimum staffing, safety, and clinical standards. Licensing requirements vary by state.
• Certified programs: Voluntarily certified by federal bodies such as SAMHSA, or accredited by independent organizations such as The Joint Commission or CARF International. Certification signals alignment with defined quality benchmarks beyond the licensing floor.

Understanding the distinction matters: a facility can be state-licensed without holding any accreditation, and the gap between those two tiers represents a wide range in clinical quality. For a structured breakdown of accreditation standards, the page on rehab accreditation and licensing provides classification detail.

The American Society of Addiction Medicine (ASAM) publishes its Patient Placement Criteria — widely known as the ASAM Criteria — which define six levels of care, from early intervention (Level 0.5) through medically managed intensive inpatient services (Level 4). A facility's stated level of care should correspond to its actual clinical infrastructure, staff credentials, and service capacity.

How It Works

Evaluating a facility follows a structured vetting sequence. The numbered steps below reflect the standard due-diligence framework recommended by SAMHSA's Treatment Locator documentation:

1. Verify state licensure — Confirm the facility holds a current license from the relevant state behavioral health agency. Most state agencies publish license lookup tools online.
2. Check accreditation status — Cross-reference with The Joint Commission's Quality Check database or CARF's Provider Search. Accredited programs have undergone external inspection against published standards.
3. Confirm SAMHSA certification (if applicable) — Opioid Treatment Programs (OTPs) administering methadone must be federally certified by SAMHSA and registered with the DEA under 42 CFR Part 8. The page on opioid treatment program regulations covers this in detail.
4. Assess clinical staffing — A compliant program employs licensed addiction counselors (LAC or CADC credentials), at minimum, with access to licensed medical staff for medically managed levels of care. The addiction medicine specialists page describes board-certification pathways through the American Board of Preventive Medicine (ABPM).
5. Evaluate treatment methodology — Evidence-based behavioral interventions, such as Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI), are documented in SAMHSA's Treatment Improvement Protocols (TIPs). Medication-assisted treatment (MAT) with buprenorphine, methadone, or naltrexone has FDA-approved indications for opioid use disorder.
6. Review financial disclosures — Facilities are required under the Affordable Care Act and parity laws (Mental Health Parity and Addiction Equity Act, MHPAEA) to disclose insurance participation. The drug rehab insurance coverage page outlines coverage obligations.
7. Examine patient rights documentation — Federal regulations at 42 CFR Part 2 govern confidentiality of SUD patient records, and facilities must provide written notice of those rights. The patient rights in drug rehab page details applicable protections under HIPAA and Part 2.

Common Scenarios

Scenario A — Accredited inpatient facility vs. non-accredited residential program
An accredited inpatient facility (ASAM Level 3.7 or 4) undergoes triennial on-site review by The Joint Commission or CARF, maintains 24-hour nursing coverage, and documents clinical outcomes. A non-accredited residential program may offer comparable amenities but lacks independent verification of its clinical protocols, staff qualifications, or safety practices. For individuals requiring co-occurring disorder treatment — combining mental health and SUD services — accreditation is a structural proxy for integrated care capacity.

Scenario B — Outpatient program selection
Intensive outpatient programs (IOPs, ASAM Level 2.1) and partial hospitalization programs (PHPs, ASAM Level 2.5) differ in service hours and medical monitoring intensity. IOPs typically deliver 9–19 hours of structured programming per week; PHPs provide 20 or more hours. A facility billing PHP rates while operating IOP hours is a documented billing irregularity flagged by CMS audits.

Scenario C — "Patient brokering" and predatory referral networks
The federal Patient Brokering Act (18 U.S.C. § 220), enacted in 2018, prohibits offering or receiving remuneration in exchange for referring patients to substance use disorder treatment facilities. Florida, California, and Texas have enacted parallel state statutes with additional enforcement mechanisms. Facilities that offer free transportation, gift cards, or paid housing contingent on admission should be evaluated against this legal framework.

Decision Boundaries

Specific features mark the boundary between a facility warranting further evaluation and one presenting categorical risk:

Red flags — categorical concerns:
- No verifiable state license or accreditation
- Inability to produce staff credential documentation on request
- Claims of proprietary or "guaranteed" cure protocols not listed in SAMHSA's National Registry of Evidence-Based Programs and Practices (NREPP) or research-based literature
- Upfront payment demands that preclude insurance verification
- Marketing that targets individuals by geography using paid referral networks (a pattern associated with patient brokering enforcement actions under 18 U.S.C. § 220)
- Refusal to provide a written treatment plan or discharge planning documentation

Positive indicators — structural quality markers:
- Joint Commission Gold Seal or CARF accreditation with a current expiration date
- SAMHSA-certified OTP status (for opioid-specific programs)
- ASAM Criteria–based intake assessment with documented level-of-care placement
- Named licensed clinical director with verifiable credentials
- Written aftercare and continuing care plan included in the admission agreement
- Transparent grievance and appeals process consistent with patient rights standards

The drug rehab facility checklist page provides a printable vetting instrument organized around these criteria categories.

References

• SAMHSA — Substance Abuse and Mental Health Services Administration
• SAMHSA National Survey of Substance Abuse Treatment Services (N-SSATS)
• SAMHSA Treatment Improvement Protocols (TIPs)
• ASAM — American Society of Addiction Medicine, Patient Placement Criteria
• The Joint Commission — Quality Check Provider Directory
• CARF International — Provider Search
• 42 CFR Part 8 — Opioid Treatment Program Standards (SAMHSA/DEA)
• 42 CFR Part 2 — Confidentiality of SUD Patient Records
• 18 U.S.C. § 220 — Federal Patient Brokering Act
• Mental Health Parity and Addiction Equity Act (MHPAEA) — CMS
• American Board of Preventive Medicine — Addiction Medicine Subspecialty